 |
|
Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease
NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease;
Elliot Rapaport, MD;
David W. Bilheimer, MD;
Aram V. Chobanian, MD;
David P. Hajjar, PhD;
C. Morton Hawkins, ScD, MPH;
Grover M. Hutchins, MD;
P. M. Kris-Etherton, PhD;
Russell V. Luepker, MD, MS;
Henry D. McIntosh, MD;
Carl J. Pepine, MD;
William A. Pettinger, MD;
Gustav Schonfeld, MD;
Doris F. Tulcin;
Michael H. Criqui, MD, MPH;
David J. Gordon, MD, PhD;
Melissa A. Austin, PhD;
Gerdo Assmann, MD;
Gerardo Heiss, MD, PhD;
Trudy L. Bush, PhD, MHS;
Rodolfo Paoletti, MD;
Lawrence L. Rudel, PhD;
Richard J. Havel, MD;
Alan Tall, MD;
Henry N. Ginsberg, MD;
William A. Bradley, PhD;
H. Bryan Brewer, Jr, MD;
John D. Brunzell, MD;
John C. LaRosa, MD;
Jacques E. Rossouw, MD;
Jussi K. Huttunen, MD;
Paul S. Bachorik, PhD;
William P. Castelli, MD;
Stephen B. Hulley, MD, MPH;
Alan Chait, MD;
Margo A. Denke, MD;
Peter D. Wood, DSc, PhD;
Antonio M. Gotto, Jr, MD, DPhil;
Ernst J. Schaefer, MD;
Barry Lewis, MD, PhD, FRCP, FRCPath
JAMA. 1993;269(4):505-510.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
GREAT progress has been made over the past 30 years in identifying cardiovascular risk factors and in developing and implementing measures to correct them. The Adult Treatment Panel of the National Cholesterol Education Program developed guidelines in 1988 that identified low-density lipoprotein (LDL) as the major atherogenic lipoprotein and high levels of LDL cholesterol (LDL-C) as the primary target for cholesterol-lowering therapy. Since these guidelines were developed, the scientific database has significantly expanded. Genetic investigations into familial dyslipidemias, advances in molecular biology, animal experiments, human observational studies, lipid metabolic studies, epidemiologic data, and the results of interventional clinical trials looking at mortality, cardiovascular end points, and angiographic changes in atheromatous lesions have created interest in further examination of the role of high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) in the pathogenesis of coronary artery disease.
To address these questions, the National Heart, Lung, and Blood Institute and the Office of
. . . [Full Text PDF of this Article]
Author Affiliations
| |
Conference and Panel Chairperson, Professor of Medicine, University of California, San Francisco, Associate Dean, San Francisco General Hospital; Professor of Internal Medicine, Chief, Division of Lipid Metabolism, University of Texas Southwestern Medical Center, Dallas; Dean and Professor of Medicine, Boston (Mass) University School of Medicine; Professor of Biochemistry and Pathology, Cornell University Medical College, New York, NY; Professor of Biochemistry, Associate Dean for Research, University of Texas School of Public Health, Houston; Professor of Pathology, Johns Hopkins University School of Medicine, Director of Autopsy Pathology, Johns Hopkins Hospital, Baltimore, Md; Professor of Nutrition, Acting Associate Dean for Research and Graduate Studies, College of Health and Human Development, Pennsylvania State University, University Park; Professor and Director, Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis; Clinical Professor of Medicine, University of Florida, Gainesville, Practicing Cardiologist, Watson Clinic, Lakeland, Fla; Professor of Medicine, Division of Cardiology, Department of Medicine, University of Florida, Gainesville; Professor of Internal Medicine and Pharmacology, Director, Midwest Hypertension Research Center, Creighton University School of Medicine, Omaha, Neb; Kountz Professor of Medicine, Director, Division of Atherosclerosis and Lipid Research, Washington University School of Medicine, St Louis, Mo; Chairperson, Research Development Council, Cystic Fibrosis Foundation, New York, NY
From the Office of Medical Applications of Research, National Institutes of Health, Bethesda, Md.
Footnotes
NIH Consensus Development Conferences are convened to evaluate available scientific information and to resolve safety and efficacy issues related to a biomedical technology. The resultant NIH Consensus Statements are intended to advance understanding of the technology or issue in question and to be useful to health professionals and the public.
NIH Consensus Statements are prepared by a nonadvocacy, nonfederal panel of experts based on (1) presentations by investigators working in areas relevant to the consensus questions during a 1  -day public session; (2) questions and statements from conference attendees during open discussion periods that are part of the public session; and (3) closed deliberations by the panel during the remainder of the second day and the morning of the third day. This statement is an independent report of the panel and is not a policy statement of the NIH or the federal government.
Reprint requests to Office of Medical Applications of Research, Federal Bldg, Room 618, National Institutes of Health, Bethesda, MD 20892 (William H. Hall). Bibliography, prepared by the National Library of Medicine, is available from the same address.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
